United States - English - NLM (National Library of Medicine)

aizant drug research solutions pvt ltd - tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) -

United States - English - NLM (National Library of Medicine)

cardinal health - tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - tenofovir disoproxil fumarate 300 mg

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , complera® , emtriva, viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see microbiology (12.4)] . truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who h

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - emtricitabine (unii: g70b4etf4s) (emtricitabine - unii:g70b4etf4s), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - emtricitabine 200 mg - truvada® , a combination of emtriva® and viread® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of hiv-1 infection in adults and pediatric patients 12 years of age and older. the following points should be considered when initiating therapy with truvada for the treatment of hiv-1 infection: - it is not recommended that truvada be used as a component of a triple nucleoside regimen. - truvada should not be coadministered with atripla® , complera® , emtriva, stribild® , viread or lamivudine-containing products [see warnings and precautions (5.4)] . - in treatment experienced patients, the use of truvada should be guided by laboratory testing and treatment history [see clinical pharmacology (12.4)] . truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinic

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg - tablet - excipient ingredients: hyprolose; hypromellose; indigo carmine aluminium lake; lactose; colloidal anhydrous silica; calcium stearate; titanium dioxide; crospovidone; macrogol 8000 - tenofovir disoproxil fumarate in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.,tenofovir disoproxil fumarate is indicated for the treatment of chronic hepatitis b in adults (see clinical trials).,tenofovir disoproxil fumarate is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e. active viral replication, persistently elevated serum alt levels or evidence of active inflammation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg - tablet - excipient ingredients: lactose; crospovidone; colloidal anhydrous silica; hypromellose; hyprolose; indigo carmine aluminium lake; titanium dioxide; calcium stearate; macrogol 8000 - tenofovir disoproxil fumarate in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.,tenofovir disoproxil fumarate is indicated for the treatment of chronic hepatitis b in adults (see clinical trials).,tenofovir disoproxil fumarate is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e. active viral replication, persistently elevated serum alt levels or evidence of active inflammation.

United States - English - NLM (National Library of Medicine)

mylan specialty l.p. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - cimduo® (lamivudine and tenofovir disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients weighing at least 35 kg. cimduo is contraindicated in patients with a previous hypersensitivity reaction to any of the components contained in the formulation. there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to cimduo during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. available data from the apr show no difference in the risk of overall major birth defects for 3tc compared to the background rate for major birth defects of 2.7% in the u.s. reference population of the metropolitan atlanta congenital defects program (macdp) (see data) . 3tc produced embryonic toxicity in rabbits at a dose that produced similar human exposures as the recommended clinical do

United States - English - NLM (National Library of Medicine)

mylan specialty l.p. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 400 mg - symfi lo® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients weighing at least 35 kg. symfi lo is contraindicated: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to symfi lo during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-containing regimens in the first trimester of pregnancy. although a causal relationship has not been established between exposure to efv in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose. in addition, fetal and embryonic toxicities occurred in rats, at a dose ten times less than the human exposur

United States - English - NLM (National Library of Medicine)

mylan specialty l.p. - efavirenz (unii: je6h2o27p8) (efavirenz - unii:je6h2o27p8), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95), tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - efavirenz 600 mg - symfi® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adult and pediatric patients weighing at least 40 kg. symfi is contraindicated: there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to symfi during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. there are retrospective case reports of neural tube defects in infants whose mothers were exposed to efv-containing regimens in the first trimester of pregnancy. although a causal relationship has not been established between exposure to efv in the first trimester and neural tube defects, similar malformations have been observed in studies conducted in monkeys at doses similar to the human dose. in addition, fetal and embryonic toxicities occurred in rats, at a dose ten times less than the human exposure at recom

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - tenofovir disoproxil fumarate (unii: ott9j7900i) (tenofovir anhydrous - unii:w4hfe001u5) - tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and pediatric patients 2 years of age and older weighing at least 10 kg. tenofovir disoproxil fumarate tablets are indicated for the treatment of chronic hepatitis b virus (hbv) in adults and pediatric patients 12 years of age and older. pediatric use information is approved for gilead sciences, inc.'s viread ® (tenofovir disoproxil fumarate) tablets. however, due to gilead sciences, inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to tenofovir disoproxil fumarate during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263.